메뉴 건너뛰기




Volumn 10, Issue , 2010, Pages

Dose escalation improves therapeutic outcome: Post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TROSPIUM CHLORIDE; MANDELIC ACID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; NORTROPANE DERIVATIVE;

EID: 77956471190     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-10-15     Document Type: Article
Times cited : (17)

References (25)
  • 2
    • 67349117295 scopus 로고    scopus 로고
    • EAU guidelines on neurogenic lower urinary tract dysfunction
    • 10.1016/j.eururo.2009.04.028. 19403235
    • EAU guidelines on neurogenic lower urinary tract dysfunction. M Stöhrer B Blok D Castro-Diaz, et al. Eur Urol 2009 56 81 88 10.1016/j.eururo.2009.04.028 19403235
    • (2009) Eur Urol , vol.56 , pp. 81-88
    • Stöhrer, M.1    Blok, B.2    Castro-Diaz, D.3
  • 4
    • 77957292014 scopus 로고    scopus 로고
    • Management of urinary incontinence in primary care
    • Royal College of Phyicians
    • Management of urinary incontinence in primary care. Scottish Intercollegiate Guidelines Network, Royal College of Phyicians 2004 http://www.sign.ac.uk
    • (2004) Scottish Intercollegiate Guidelines Network
  • 5
    • 68249084476 scopus 로고    scopus 로고
    • Pharmacological treatment of overactive bladder: Report from the International Consultation on Incontinence
    • 10.1097/MOU.0b013e32832ce8a4. 19448545
    • Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. KE Andersson CR Chapple L Cardozo, et al. Curr Opin Urol 2009 19 380 394 10.1097/MOU.0b013e32832ce8a4 19448545
    • (2009) Curr Opin Urol , vol.19 , pp. 380-394
    • Andersson, K.E.1    Chapple, C.R.2    Cardozo, L.3
  • 6
    • 47949098266 scopus 로고    scopus 로고
    • The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis
    • 10.1016/j.eururo.2008.06.047. 18599186
    • The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. CR Chapple V Khullar Z Gabriel, et al. Eur Urol 2008 54 543 562 10.1016/j.eururo.2008.06.047 18599186
    • (2008) Eur Urol , vol.54 , pp. 543-562
    • Chapple, C.R.1    Khullar, V.2    Gabriel, Z.3
  • 7
    • 34247271263 scopus 로고    scopus 로고
    • Maximizing anticholinergic therapy for overactive bladder: Has the ceiling been reached?
    • 10.1111/j.1464-410X.2007.06881.x. 17488367
    • Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? S MacDiarmid, BJU Int 2007 99 Suppl 3 8 12 10.1111/j.1464-410X.2007.06881.x 17488367
    • (2007) BJU Int , vol.99 , Issue.SUPPL. 3 , pp. 8-12
    • MacDiarmid, S.1
  • 8
    • 32444441009 scopus 로고    scopus 로고
    • Using anticholinergics to treat overactive bladder: The issue of treatment tolerability
    • DOI 10.1016/j.amjmed.2005.12.011, PII S0002934305011915
    • Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. DR Staskin SA MacDiarmid, Am J Med 2006 119 3A 9S 15S 10.1016/j.amjmed.2005.12.011 (Pubitemid 43227968)
    • (2006) American Journal of Medicine , vol.119 , Issue.3 SUPPL. 1
    • Staskin, D.R.1    MacDiarmid, S.A.2
  • 9
    • 32444448625 scopus 로고    scopus 로고
    • Pharmacologic management of overactive bladder: Practical options for the primary care physician
    • DOI 10.1016/j.amjmed.2005.12.013, PII S0002934305011939
    • Pharmacological management of overactive bladder: practical options for the primary care physician. DR Staskin SA MacDiarmid, Am J Med 2006 199 3A 24S 28S 10.1016/j.amjmed.2005.12.013 (Pubitemid 43227970)
    • (2006) American Journal of Medicine , vol.119 , Issue.3 SUPPL. 1
    • Staskin, D.R.1    MacDiarmid, S.A.2
  • 10
    • 1542756575 scopus 로고    scopus 로고
    • Overactive bladder: Improving the efficacy of anticholinergics by dose escalation
    • 10.1007/s11934-003-0025-z. 14622497
    • Overactive bladder: improving the efficacy of anticholinergics by dose escalation. SA MacDiarmid, Curr Urol Rep 2003 4 446 451 10.1007/s11934-003-0025- z 14622497
    • (2003) Curr Urol Rep , vol.4 , pp. 446-451
    • MacDiarmid, S.A.1
  • 11
    • 67649336782 scopus 로고    scopus 로고
    • Efficacy and tolerability of add-on trospium chloride in patients with benign prostate syndrome and overactive bladder: A non-interventional trial showing use of flexible dosing
    • 10.3834/uij.1944-5784.2009.04.02
    • Efficacy and tolerability of add-on trospium chloride in patients with benign prostate syndrome and overactive bladder: a non-interventional trial showing use of flexible dosing. A Wiedemann G Neumann C Neumeister, et al. UIJ 2009 2 2 10.3834/uij.1944-5784.2009.04.02
    • (2009) UIJ , vol.2 , Issue.2
    • Wiedemann, A.1    Neumann, G.2    Neumeister, C.3
  • 13
    • 74549185973 scopus 로고    scopus 로고
    • Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: Results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial
    • 10.1016/j.clinthera.2009.11.005. 20109997
    • Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. M Zellner H Madersbacher H Palmtag, et al. Clin Ther 2009 31 2519 2539 10.1016/j.clinthera.2009.11.005 20109997
    • (2009) Clin Ther , vol.31 , pp. 2519-2539
    • Zellner, M.1    Madersbacher, H.2    Palmtag, H.3
  • 14
    • 0032829435 scopus 로고    scopus 로고
    • Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
    • 10.1016/S0022-5347(05)68810-6. 10332441
    • Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. RU Anderson D Mobley B Blank, et al. J Urol 1999 161 6 1809 1812 10.1016/S0022-5347(05)68810-6 10332441
    • (1999) J Urol , vol.161 , Issue.6 , pp. 1809-1812
    • Anderson, R.U.1    Mobley, D.2    Blank, B.3
  • 15
    • 0032838886 scopus 로고    scopus 로고
    • Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence
    • 10.1016/S0090-4295(99)00259-9. 10475346
    • Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. DM Gleason J Susset C White, et al. Urology 1999 54 3 420 423 10.1016/S0090-4295(99)00259-9 10475346
    • (1999) Urology , vol.54 , Issue.3 , pp. 420-423
    • Gleason, D.M.1    Susset, J.2    White, C.3
  • 16
    • 0034088434 scopus 로고    scopus 로고
    • Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence
    • 10.1016/S0029-7844(99)00661-4. 10775736
    • Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. E Versi R Appell D Mobley, et al. Obstet Gynecol 2000 95 718 721 10.1016/S0029-7844(99)00661-4 10775736
    • (2000) Obstet Gynecol , vol.95 , pp. 718-721
    • Versi, E.1    Appell, R.2    Mobley, D.3
  • 17
    • 33645003584 scopus 로고    scopus 로고
    • A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: Balancing efficacy with severity of dry mouth
    • 10.1111/j.1464-410X.2005.06031.x
    • A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. J Corcos R Casey A Patrick, et al. BJU Int 2005 97 520 527 10.1111/j.1464-410X.2005.06031.x
    • (2005) BJU Int , vol.97 , pp. 520-527
    • Corcos, J.1    Casey, R.2    Patrick, A.3
  • 18
    • 14644417909 scopus 로고    scopus 로고
    • 3-selective receptor antagonist
    • 10.1111/j.1464-410X.2005.05343.x. 15705084
    • 3-selective receptor antagonist. W Steers J Corcos j Foote, et al. BJU Int 2005 95 580 586 10.1111/j.1464-410X.2005.05343.x 15705084
    • (2005) BJU Int , vol.95 , pp. 580-586
    • Steers, W.1    Corcos, J.2    Foote, J.3
  • 19
    • 23944452838 scopus 로고    scopus 로고
    • A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial
    • 15990220
    • A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. CR Chapple R Martinez-Garcia L Selvaggi, et al. Eur Urol 2005 48 464 470 15990220
    • (2005) Eur Urol , vol.48 , pp. 464-470
    • Chapple, C.R.1    Martinez-Garcia, R.2    Selvaggi, L.3
  • 20
    • 42749089770 scopus 로고    scopus 로고
    • Fesoterodine dose response in subjects with overactive bladder syndrome
    • 10.1016/j.urology.2007.12.017. 18342923
    • Fesoterodine dose response in subjects with overactive bladder syndrome. VK Khullar ES Rovner R Dmochowski, et al. Urology 2008 71 839 843 10.1016/j.urology.2007.12.017 18342923
    • (2008) Urology , vol.71 , pp. 839-843
    • Khullar, V.K.1    Rovner, E.S.2    Dmochowski, R.3
  • 21
    • 72249114712 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder
    • Erratum in: Urology 2010, 75(6): 1519. 10.1016/j.urology.2009.09.018. 19931895
    • Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. RR Dmochowski KM Peters JD Morrow, et al. Urology 2010 75 1 62 68 Erratum in: Urology 2010, 75 (6): 1519 10.1016/j.urology.2009.09.018 19931895
    • (2010) Urology , vol.75 , Issue.1 , pp. 62-68
    • Dmochowski, R.R.1    Peters, K.M.2    Morrow, J.D.3
  • 22
    • 33744798224 scopus 로고    scopus 로고
    • Pharmacotherapy for neurogenic detrusor overactivity
    • 10.1097/01.phm.0000219229.92056.c2. 16715024
    • Pharmacotherapy for neurogenic detrusor overactivity. MB Chancellor RU Anderson TB Boone, Am J Phys Med Rehabil 2006 85 6 536 545 10.1097/01.phm. 0000219229.92056.c2 16715024
    • (2006) Am J Phys Med Rehabil , vol.85 , Issue.6 , pp. 536-545
    • Chancellor, M.B.1    Anderson, R.U.2    Boone, T.B.3
  • 23
    • 0037590258 scopus 로고    scopus 로고
    • Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury
    • 12828295
    • Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. M O'Leary JR Erickson CP Smith, et al. J Spinal Cord Med 2003 26 159 162 12828295
    • (2003) J Spinal Cord Med , vol.26 , pp. 159-162
    • O'Leary, M.1    Erickson, J.R.2    Smith, C.P.3
  • 24
    • 0347759842 scopus 로고    scopus 로고
    • Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
    • 10.1097/01.ju.0000103274.38694.b1. 14713802
    • Can higher doses of oxybutynin improve efficacy in neurogenic bladder? N Bennett M O'Leary AS Patel, et al. J Urol 2004 171 749 751 10.1097/01.ju. 0000103274.38694.b1 14713802
    • (2004) J Urol , vol.171 , pp. 749-751
    • Bennett, N.1    O'Leary, M.2    Patel, A.S.3
  • 25
    • 0030442725 scopus 로고    scopus 로고
    • Muscarinic receptor subtypes and smooth function
    • 8981565
    • Muscarinic receptor subtypes and smooth function. RM Eglen SS Hedge N Watson, Pharmacol Rev 1996 48 531 565 8981565
    • (1996) Pharmacol Rev , vol.48 , pp. 531-565
    • Eglen, R.M.1    Hedge, S.S.2    Watson, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.